G

Gilberto de Castro

Twitter (United States)

ORCID: 0000-0001-8765-3044

Publishes on Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Head and Neck Cancer Studies. 459 papers and 31k citations.

459Publications

31kTotal Citations

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Head and Neck Cancer Studies Lung Cancer Diagnosis and Treatment Lung Cancer Research Studies

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Paul Baas, Dong‐Wan Kim et al.|The Lancet|2015

Cited by 6.5k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al.|The Lancet|2019

Cited by 3.3kOpen Access

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al.|The Lancet|2019

Cited by 3.2kOpen Access

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari et al.|The Lancet|2017

Cited by 1.1k

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Martine Piccart, Richard D. Gelber et al.|The Lancet|2017

Cited by 1kOpen Access